Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119227519> ?p ?o ?g. }
- W3119227519 endingPage "69" @default.
- W3119227519 startingPage "64" @default.
- W3119227519 abstract "Single-fraction radiotherapy (SFRT) offers equal pain relief for uncomplicated painful bone metastases as compared to multiple-fraction radiotherapy (MFRT). Despite this evidence, the adoption of SFRT has been poor with published rates of SFRT for uncomplicated bone metastases ranging from <10% to 70%. We aimed to evaluate the adoption of SFRT and its evolution over time following the more formal endorsement of the international guidelines in our centre starting from 2013.We performed a retrospective review of fractionation schedules at our centre for painful uncomplicated bone metastases from January 2013 until December 2017. Only patients treated with 1 × 8 Gy (SFRT-group) or 10 × 3 Gy (MFRT-group) were included. We excluded other fractionation schedules, primary cancer of the bone and post-operative radiotherapy. Uncomplicated was defined as painful but not associated with impending fracture, existing fracture or existing neurological compression. Temporal trends in SFRT/MFRT usage and overall survival were investigated. We performed a lesion-based patterns of care analysis and a patient-based survival analysis. Mann-Whitney U and Chi-square test were used to assess differences between fractionation schedules and temporal trends in prescription, with Kaplan-Meier estimates used for survival analysis (p-value <0.05 considered significant).Overall, 352 patients and 594 uncomplicated bone metastases met inclusion criteria. Patient characteristics were comparable between SFRT and MFRT, except for age. Overall, SFRT was used in 92% of all metastases compared to 8% for MFRT. SFRT rates increased throughout the study period from 85% in 2013 to 95% in 2017 (p = 0.06). Re-irradiation rates were higher in patients treated with SFRT (14%) as compared to MFRT (4%) (p = 0.046). Four-week mortality and median overall survival did not differ significantly between SFRT and MFRT (17% vs 18%, p = 0.8 and 25 weeks vs 38 weeks, p = 0.97, respectively).Adherence to the international guidelines for SFRT for uncomplicated bone metastasis was high and increased over time to 95%, which is the highest reported rate in literature." @default.
- W3119227519 created "2021-01-18" @default.
- W3119227519 creator A5005443672 @default.
- W3119227519 creator A5005827644 @default.
- W3119227519 creator A5011864520 @default.
- W3119227519 creator A5013836474 @default.
- W3119227519 creator A5022705784 @default.
- W3119227519 creator A5022864667 @default.
- W3119227519 creator A5027236935 @default.
- W3119227519 creator A5030359311 @default.
- W3119227519 creator A5044960222 @default.
- W3119227519 creator A5055056736 @default.
- W3119227519 creator A5070502839 @default.
- W3119227519 creator A5073205467 @default.
- W3119227519 creator A5082930226 @default.
- W3119227519 creator A5083566572 @default.
- W3119227519 date "2021-03-01" @default.
- W3119227519 modified "2023-10-18" @default.
- W3119227519 title "Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre" @default.
- W3119227519 cites W1102190518 @default.
- W3119227519 cites W1873634792 @default.
- W3119227519 cites W1967352289 @default.
- W3119227519 cites W1975690193 @default.
- W3119227519 cites W1983558676 @default.
- W3119227519 cites W1998887983 @default.
- W3119227519 cites W2005356522 @default.
- W3119227519 cites W2012034012 @default.
- W3119227519 cites W2018038855 @default.
- W3119227519 cites W2023085317 @default.
- W3119227519 cites W2025442147 @default.
- W3119227519 cites W2031145335 @default.
- W3119227519 cites W2047930883 @default.
- W3119227519 cites W2053787128 @default.
- W3119227519 cites W2068518767 @default.
- W3119227519 cites W2075843463 @default.
- W3119227519 cites W2088553468 @default.
- W3119227519 cites W2090681697 @default.
- W3119227519 cites W2113235727 @default.
- W3119227519 cites W2119941303 @default.
- W3119227519 cites W2129554678 @default.
- W3119227519 cites W2140902814 @default.
- W3119227519 cites W2252887828 @default.
- W3119227519 cites W2775321189 @default.
- W3119227519 cites W2790983120 @default.
- W3119227519 cites W2939770857 @default.
- W3119227519 cites W2944301866 @default.
- W3119227519 cites W5267548 @default.
- W3119227519 doi "https://doi.org/10.1016/j.ctro.2021.01.004" @default.
- W3119227519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7829104" @default.
- W3119227519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33532632" @default.
- W3119227519 hasPublicationYear "2021" @default.
- W3119227519 type Work @default.
- W3119227519 sameAs 3119227519 @default.
- W3119227519 citedByCount "5" @default.
- W3119227519 countsByYear W31192275192021 @default.
- W3119227519 countsByYear W31192275192023 @default.
- W3119227519 crossrefType "journal-article" @default.
- W3119227519 hasAuthorship W3119227519A5005443672 @default.
- W3119227519 hasAuthorship W3119227519A5005827644 @default.
- W3119227519 hasAuthorship W3119227519A5011864520 @default.
- W3119227519 hasAuthorship W3119227519A5013836474 @default.
- W3119227519 hasAuthorship W3119227519A5022705784 @default.
- W3119227519 hasAuthorship W3119227519A5022864667 @default.
- W3119227519 hasAuthorship W3119227519A5027236935 @default.
- W3119227519 hasAuthorship W3119227519A5030359311 @default.
- W3119227519 hasAuthorship W3119227519A5044960222 @default.
- W3119227519 hasAuthorship W3119227519A5055056736 @default.
- W3119227519 hasAuthorship W3119227519A5070502839 @default.
- W3119227519 hasAuthorship W3119227519A5073205467 @default.
- W3119227519 hasAuthorship W3119227519A5082930226 @default.
- W3119227519 hasAuthorship W3119227519A5083566572 @default.
- W3119227519 hasBestOaLocation W31192275191 @default.
- W3119227519 hasConcept C141071460 @default.
- W3119227519 hasConcept C155806632 @default.
- W3119227519 hasConcept C509974204 @default.
- W3119227519 hasConcept C71924100 @default.
- W3119227519 hasConceptScore W3119227519C141071460 @default.
- W3119227519 hasConceptScore W3119227519C155806632 @default.
- W3119227519 hasConceptScore W3119227519C509974204 @default.
- W3119227519 hasConceptScore W3119227519C71924100 @default.
- W3119227519 hasLocation W31192275191 @default.
- W3119227519 hasLocation W31192275192 @default.
- W3119227519 hasLocation W31192275193 @default.
- W3119227519 hasLocation W31192275194 @default.
- W3119227519 hasLocation W31192275195 @default.
- W3119227519 hasOpenAccess W3119227519 @default.
- W3119227519 hasPrimaryLocation W31192275191 @default.
- W3119227519 hasRelatedWork W2002120878 @default.
- W3119227519 hasRelatedWork W2003938723 @default.
- W3119227519 hasRelatedWork W2047967234 @default.
- W3119227519 hasRelatedWork W2118496982 @default.
- W3119227519 hasRelatedWork W2364998975 @default.
- W3119227519 hasRelatedWork W2369162477 @default.
- W3119227519 hasRelatedWork W2439875401 @default.
- W3119227519 hasRelatedWork W4238867864 @default.
- W3119227519 hasRelatedWork W2519357708 @default.
- W3119227519 hasRelatedWork W2525756941 @default.
- W3119227519 hasVolume "27" @default.